NVAX
Novavax
October 6, 2026 · intraday
- Rarity
- 1.89
- Peak move
- −13.14%
- Float cap
- $1.9B
Novavax is a Gaithersburg, Maryland-based vaccine company that develops recombinant protein-based nanoparticle vaccines and its proprietary Matrix-M adjuvant. It sells its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, to governments and health systems, and licenses its technology to partners such as Sanofi, Takeda and the Serum Institute of India, which uses Matrix-M in its malaria vaccine. Its pipeline spans seasonal influenza, COVID-influenza combinations, RSV and other infectious-disease candidates.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 0 from SEC or newswire · 0 timed with the movepublic_healthDarya Shipilova, a 28-year-old lab technician at the Irkutsk Anti-Plague Research Institute in Siberia, died of pneumonia of unknown origin, prompting monitoring of about 189-200 contacts, while Russia's Rospotrebnadzor said samples contained no workplace-related microorganisms and the WHO assessed general-population risk as low.
- Key event
borrow_cost_spikeNovavax short interest stood at 30.43% of float, about 49.9 million shares as of mid-September, requiring roughly 10 trading days of average volume to cover, and Monday's volume equaled about 40% of the short position, fueling a squeeze.
- Key event
regulatory_approvalNovavax partners Sanofi and Takeda received approvals for the updated XFG-adapted version of Nuvaxovid for the 2026/27 season in the United States, the European Union and Japan, with Novavax collecting royalties on partner sales.
demand_signalVaxcyte's VAX-31 Phase 3 win against Pfizer's Prevnar 20 and Merck's Capvaxive revived interest across vaccine makers, lifting peers including Moderna and Arcturus and pulling Novavax into the sector bid, though Novavax has no pneumococcal vaccine program.
- Key event
clinical_readoutVaxcyte reported positive topline results from the pivotal Phase 3 OPUS-1 trial of its 31-valent pneumococcal conjugate vaccine VAX-31, meeting all prespecified primary immunogenicity and safety endpoints versus Pfizer's Prevnar 20 and Merck's Capvaxive in adults 50 and older, with Vaxcyte shares rising about 50%.
major_contractNovavax's Matrix-M adjuvant has been licensed by four of the world's ten largest pharmaceutical companies, including Pfizer's up-to-$500M milestone deal, which management frames as validation of its shift from COVID vaccine maker to platform licensor.
regulatory_approvalThe US CDC approved Novavax's two-dose COVID-19 vaccine as a primary series for adults, offering an alternative for the unvaccinated.